Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Improved detection of botulinum neurotoxin serotype A by Endopep-MS through peptide substrate modification.

Wang D, Baudys J, Ye Y, Rees JC, Barr JR, Pirkle JL, Kalb SR.

Anal Biochem. 2013 Jan 15;432(2):115-23. doi: 10.1016/j.ab.2012.09.021. Epub 2012 Sep 24.

2.

Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates.

Wang D, Krilich J, Baudys J, Barr JR, Kalb SR.

Bioorg Med Chem. 2015 Jul 1;23(13):3667-73. doi: 10.1016/j.bmc.2015.04.012. Epub 2015 Apr 10.

3.

Improved detection of botulinum neurotoxin type A in stool by mass spectrometry.

Wang D, Baudys J, Kalb SR, Barr JR.

Anal Biochem. 2011 May 1;412(1):67-73. doi: 10.1016/j.ab.2011.01.025. Epub 2011 Jan 26.

PMID:
21276417
4.

Optimization of SNAP-25-derived peptide substrate for improved detection of botulinum A in the Endopep-MS assay.

Rosen O, Feldberg L, Dor E, Gura S, Zichel R.

Anal Biochem. 2017 Jul 1;528:34-37. doi: 10.1016/j.ab.2017.04.012. Epub 2017 Apr 24.

PMID:
28450105
5.

Optimization of peptide substrates for botulinum neurotoxin E improves detection sensitivity in the Endopep-MS assay.

Wang D, Krilich J, Baudys J, Barr JR, Kalb SR.

Anal Biochem. 2015 Jan 1;468:15-21. doi: 10.1016/j.ab.2014.08.026. Epub 2014 Sep 16.

6.

Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.

Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR.

PLoS One. 2010 Aug 17;5(8):e12237. doi: 10.1371/journal.pone.0012237.

7.

A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase-liquid chromatography-tandem mass spectrometry/multiple reaction monitoring assay.

Rosen O, Feldberg L, Gura S, Zichel R.

Anal Biochem. 2015 Mar 15;473:7-10. doi: 10.1016/j.ab.2014.09.016. Epub 2014 Sep 30.

PMID:
25277815
8.

Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry.

Wang D, Baudys J, Hoyt KM, Barr JR, Kalb SR.

Anal Bioanal Chem. 2017 Aug;409(20):4779-4786. doi: 10.1007/s00216-017-0421-8. Epub 2017 Jun 2.

9.

Botulinum neurotoxin detection and differentiation by mass spectrometry.

Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL.

Emerg Infect Dis. 2005 Oct;11(10):1578-83.

10.

Quantification of botulinum neurotoxin serotypes A and B from serum using mass spectrometry.

Parks BA, Shearer JD, Baudys J, Kalb SR, Sanford DC, Pirkle JL, Barr JR.

Anal Chem. 2011 Dec 1;83(23):9047-53. doi: 10.1021/ac201910q. Epub 2011 Nov 4.

PMID:
22017298
11.

Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay.

Rosen O, Feldberg L, Gura S, Zichel R.

Anal Biochem. 2014 Jul 1;456:50-2. doi: 10.1016/j.ab.2014.03.024. Epub 2014 Apr 8.

PMID:
24721293
12.

From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry.

Boyer AE, Moura H, Woolfitt AR, Kalb SR, McWilliams LG, Pavlopoulos A, Schmidt JG, Ashley DL, Barr JR.

Anal Chem. 2005 Jul 1;77(13):3916-24.

PMID:
15987092
13.

Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR.

PLoS One. 2009;4(4):e5355. doi: 10.1371/journal.pone.0005355. Epub 2009 Apr 28.

14.

Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.

Kalb SR, Goodnough MC, Malizio CJ, Pirkle JL, Barr JR.

Anal Chem. 2005 Oct 1;77(19):6140-6.

PMID:
16194071
15.

Mass Spectrometric Detection of Bacterial Protein Toxins and Their Enzymatic Activity.

Kalb SR, Boyer AE, Barr JR.

Toxins (Basel). 2015 Aug 31;7(9):3497-511. doi: 10.3390/toxins7093497. Review.

16.

Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.

Schmidt JJ, Stafford RG.

Appl Environ Microbiol. 2003 Jan;69(1):297-303. Erratum in: Appl Environ Microbiol. 2003 May;69(5):3025.

17.

Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.

Wang D, Krilich J, Pellett S, Baudys J, Tepp WH, Barr JR, Johnson EA, Kalb SR.

Biochim Biophys Acta. 2013 Dec;1834(12):2722-8. doi: 10.1016/j.bbapap.2013.09.007. Epub 2013 Oct 2.

18.

Studies on botulinum neurotoxins type /C1 and mosaic/DC using Endopep-MS and proteomics.

Moura H, Terilli RR, Woolfitt AR, Gallegos-Candela M, McWilliams LG, Solano MI, Pirkle JL, Barr JR.

FEMS Immunol Med Microbiol. 2011 Apr;61(3):288-300. doi: 10.1111/j.1574-695X.2010.00774.x. Epub 2011 Jan 26.

19.

Different substrate recognition requirements for cleavage of synaptobrevin-2 by Clostridium baratii and Clostridium botulinum type F neurotoxins.

Kalb SR, Baudys J, Egan C, Smith TJ, Smith LA, Pirkle JL, Barr JR.

Appl Environ Microbiol. 2011 Feb;77(4):1301-8. doi: 10.1128/AEM.01662-10. Epub 2010 Dec 17.

20.

A simple, rapid and sensitive FRET assay for botulinum neurotoxin serotype B detection.

Guo J, Xu C, Li X, Chen S.

PLoS One. 2014 Dec 1;9(12):e114124. doi: 10.1371/journal.pone.0114124. eCollection 2014.

Supplemental Content

Support Center